Early MRI outcomes in participants with a first clinical demyelinating event at risk of multiple sclerosis in the ORACLE-MS study

BACKGROUND: In the Phase 3, 96-week ORACLE-MS study, cladribine tablets 10 mg (3.5 or 5.25 mg/kg cumulative dosage over two years) significantly reduced lesions associated with multiple sclerosis versus placebo in participants following a first clinical demyelinating event (FCDE). OBJECTIVE: To dete...

Descripción completa

Detalles Bibliográficos
Autores principales: Freedman, Mark S, Coyle, Patricia K, Comi, Giancarlo, L Scarberry, Susan, Damian, Doris, Hyvert, Yann, Dangond, Fernando, Galazka, Andrew, Jack, Dominic, Lebson, Lori A, Leist, Thomas P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Original Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7925953/
https://www.ncbi.nlm.nih.gov/pubmed/33717501
http://dx.doi.org/10.1177/2055217321990852

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7925953/
https://www.ncbi.nlm.nih.gov/pubmed/33717501
http://dx.doi.org/10.1177/2055217321990852

Ejemplares similares